Literature DB >> 25516688

Diagnostically untypable hepatitis C virus variants: it is time to resolve the problem.

Muhammad Sohail Afzal1, Muhammad Yousaf Khan1, Muhammad Ammar1, Sadia Anjum1, Najm Us Sahar Sadaf Zaidi1.   

Abstract

Pakistan is a low income country with more than 10 million hepatitis C virus (HCV) infections and the burden is on continuous raise. Accurate viral genotyping is very critical for proper treatment of the infected individuals as the sustained virological response of the standard antiviral interferon therapy is genotype dependent. We observed at our diagnostic center that 15.6% of HCV patient's samples were not genotype-able by using Ohno et al method. The genotyped samples showed that 3a (68.3%) is the major prevalent genotype in Pakistan followed by 2a (10.3%), 3b (2.6%), 1b (1.5%), 2b (1.2%) and 1a (0.5%). Presence of large number of untypable HCV variants in the current study highlights an important issue of health care setup in Pakistan. Untypable HCV cases create difficulties in treatment of these patients. The problem of routine diagnostics setup of Pakistan should be addressed on priority basis to facilitate the medical professionals in patient's treatment and to help in achieving the maximum sustained virological response.

Entities:  

Keywords:  Antiviral interferon therapy; Diagnostics; Genotypes; Hepatitis C virus; Pakistan; Untypable variants

Mesh:

Substances:

Year:  2014        PMID: 25516688      PMCID: PMC4265635          DOI: 10.3748/wjg.v20.i46.17690

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience.

Authors:  Muhammad Idrees; Amreek Lal; Fayyaz Ahmed Malik; Abrar Hussain; Irshad ur Rehman; Haji Akbar; Sadia Butt; Muhammad Ali; Liaqat Ali; Fayyaz Ahmed Malik
Journal:  Infect Genet Evol       Date:  2010-12-22       Impact factor: 3.342

2.  Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan.

Authors:  Muhammad Sohail Afzal; Sadia Tahir; Amna Salman; Tahir Ahmed Baig; Talha Shafi; Najm Us Sahar Sadaf Zaidi; Ishtiaq Qadri
Journal:  J Infect Dev Ctries       Date:  2011-07-04       Impact factor: 0.968

3.  HCV genotype distribution and possible transmission risks in Lahore, Pakistan.

Authors:  Waqar Ahmad; Bushra Ijaz; Fouzia-Tahir Javed; Shah Jahan; Imran Shahid; Fawad-Mumtaz Khan; Sajida Hassan
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

4.  Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.

Authors:  Sadia Anjum; Ahmed Wahid; Muhammad Sohail Afzal; Anna Albecka; Khaled Alsaleh; Tahir Ahmad; Thomas F Baumert; Czeslaw Wychowski; Ishtiaq Qadri; François Penin; Jean Dubuisson
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

5.  Hepatitis C virus genotype 3a with phylogenetically distinct origin is circulating in Pakistan.

Authors:  Irshad-Ur Rehman; Muhammad Idrees; Muhammad Ali; Liaqat Ali; Sadia Butt; Abrar Hussain; Haji Akbar; Samia Afzal
Journal:  Genet Vaccines Ther       Date:  2011-01-06

6.  Prevalence of hepatitis B and C in internally displaced persons of war against terrorism in Swat, Pakistan.

Authors:  Abdul Rauf; Muhammad Shahid Nadeem; Akbar Ali; Muhammad Iqbal; Muhammad Mustafa; Muhammad Muzammal Latif; Muhammad Zahid Latif; Nisar Ahmed; Abdul Rauf Shakoori
Journal:  Eur J Public Health       Date:  2010-07-03       Impact factor: 3.367

7.  Genotype variation of hepatitis C virus in District Buner Swat.

Authors:  Khalid Mahmood; Noor Mohammad
Journal:  J Ayub Med Coll Abbottabad       Date:  2011 Oct-Dec

8.  Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan.

Authors:  Sher Zaman Safi; Yasir Waheed; Joharia Sadat; Sadia Salahuddin; Umar Saeed; Muhammad Ashraf
Journal:  Asian Pac J Trop Biomed       Date:  2012-07

9.  Seroprevalence of hepatitis B and C genotypes among young apparently healthy females of karachi-pakistan.

Authors:  St Hakim; Su Kazmi; O Bagasra
Journal:  Libyan J Med       Date:  2008-06-01       Impact factor: 1.657

10.  Comparison of HCV prevalence in pakistan and iran; an insight into future.

Authors:  Muhammad Sohail Afzal; Tahir Ahmed; Najam Us Sahar Sadaf Zaidi
Journal:  Hepat Mon       Date:  2014-01-12       Impact factor: 0.660

View more
  6 in total

1.  Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective.

Authors:  Muhammad Sohail Afzal
Journal:  World J Hepatol       Date:  2016-09-18

Review 2.  Update on hepatitis B and C virus diagnosis.

Authors:  Livia Melo Villar; Helena Medina Cruz; Jakeline Ribeiro Barbosa; Cristianne Sousa Bezerra; Moyra Machado Portilho; Letícia de Paula Scalioni
Journal:  World J Virol       Date:  2015-11-12

Review 3.  Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data.

Authors:  Muhammad Umer; Mazhar Iqbal
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

4.  Prevalence of hepatitis-C virus genotypes and potential transmission risks in Malakand Khyber Pakhtunkhwa, Pakistan.

Authors:  Nausheen Nazir; Muhammad Rasul Jan; Amjad Ali; Muhammad Asif; Muhammad Idrees; Mohammad Nisar; Muhammad Zahoor; Naser M Abd El-Salam
Journal:  Virol J       Date:  2017-08-22       Impact factor: 4.099

5.  Association of genotypes with viral load and biochemical markers in HCV-infected Sindhi patients.

Authors:  Saba Riaz; Muhammad Faisal Bashir; Saleem Haider; Naeem Rahid
Journal:  Braz J Microbiol       Date:  2016-07-26       Impact factor: 2.476

6.  Recent HCV genotype changing pattern in the Khyber Pakhtunkhwa province of Pakistan; is it pointing out a forthcoming problem?

Authors:  Muhammad Sohail Afzal; Zaheer Hussain Shah; Haroon Ahmed
Journal:  Braz J Infect Dis       Date:  2016-03-08       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.